Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Dexia To Sell Asset Management Division To GCS Capital For EUR 380 Mln

Franco-Belgian bank Dexia SA (DEX.L, DXBGF.PK) Thursday announced it has signed a share purchase agreement with Hong Kong-based strategic investor GCS Capital for the sale of Dexia Asset Management for 380 million euros, which will be subject to an adjustment at closing.

According to Dexia, the scope of the sale includes full perimeter of Dexia Asset Management that comes under the orderly resolution of the Dexia Group undertaken in October last year.

Finalization of the deal, subject to approval of regulatory authorities and the European Commission, is expected in the first quarter of 2013.

Earlier last month, Dexia had announced that Belgian and French states, which control Dexia, have agreed to pump in 5.5 billion euros of fresh capital to the debt stricken lender, after the bank reported hefty losses and write-downs.

Karel De Boeck, CEO of Dexia Group said, "We actively continue to implement the Dexia Group orderly resolution plan announced in October 2011. This disposal gives Dexia Asset Management an opportunity to continue its commercial development and to expand its current platform into new growth areas."

The company stated that the transaction will not have any significant impact on its consolidated results and will not change significantly its solvency ratios.

GCS Capital has establishments in London and Beijing, and is supported by large institutional investors from Greater China and Qatar.

Last month, the troubled bank Dexia had reported a third-quarter net loss of 1.23 billion euros, reflecting mainly impairments and write-downs related to the sale of assets.

On September 28, Dexia completed divestment of its 99.84 percent shareholding in DenizBank AS to Sberbank and on October 5, the divestment of its 99.906 percent shareholding in Banque Internationale à Luxembourg to Precision Capital.

In Brussels, Dexia closed Wednesday's regular trading at 0.07 euros, down 22.22 percent, on 24.49 million shares.

Register
To receive FREE breaking news email alerts for Dexia and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.